Long COVID, ME/CFS, fibromyalgia, mold-related illness, and MCAS carry different labels but share the same underlying biology. Persistent immune dysregulation, mitochondrial dysfunction, and unresolved inflammation are the targets regenerative medicine works on directly.
By Jed Ryan, Founder and CEO · Reviewed by Adas Darinskas, PhD, Chief Science Officer · Published · Last reviewed
“Chronic illness” here refers to the cluster of conditions that defy single-system explanation: post-viral syndromes, persistent immune dysregulation, mitochondrial-driven fatigue, mast cell over-activation, and the multi-system collapse that often follows them. Patients in this category have usually seen many specialists, picked up a string of partial labels, and been told repeatedly that nothing is wrong, even though they know something is.
We work with the following in this cluster:
Diagnostically they look unrelated. Underneath, they share the same biological signature, and that is the level where a regenerative protocol can do useful work.
Across the chronic-illness cluster, five interlocking systems tend to be dysfunctional at the same time. Part of what makes these conditions so hard to treat conventionally is that fixing any one in isolation rarely helps, because the others pull the patient back toward dysfunction.
After acute infection or chronic exposure, the immune system fails to fully return to baseline. Pro-inflammatory cytokines stay elevated; regulatory mechanisms stay suppressed. The immune response keeps running as though an infection is still present, even when no test can find one.
Cellular energy production fails where it matters most: ATP synthesis. Patients describe profound fatigue, post-exertional malaise, and an inability to recover from minor stressors, all signs of mitochondria that cannot keep up.
Reactive oxygen species accumulate faster than antioxidant systems can clear them. Membrane lipids, proteins, and DNA take damage. The cellular environment becomes inhospitable to repair.
The gut barrier is supposed to be selectively permeable. In chronic illness it usually isn’t: bacterial fragments and food antigens cross into circulation and keep systemic immune activation going. Many chronic-illness symptoms originate in the gut even when the gut isn’t the obvious complaint.
For a subset of patients, an underlying infection (Borrelia, EBV, persistent SARS-CoV-2 fragments, mycotoxin exposure) drives ongoing immune activation. The infection itself may be subclinical; the immune response to it isn’t.
Conventional care tends to take these one at a time: antimicrobials for infection, anti-inflammatories for inflammation, supplements for mitochondria. Regenerative medicine works at the cellular level, where these systems overlap, rather than treating each in isolation.
Four primary mechanisms do most of the work in regenerative protocols for this cluster.
Mesenchymal stem cells transfer functional mitochondria to stressed cells through tunneling nanotubes and extracellular vesicles. In conditions where mitochondrial dysfunction is the central problem, this is one of the most directly relevant mechanisms in cellular therapy.
MSCs and MSC-derived exosomes shift T-cell populations toward regulatory phenotypes, reduce pro-inflammatory cytokine output, and dampen the persistent immune activation that characterizes post-viral and post-exposure syndromes.
Where conventional anti-inflammatories work on a single pathway, the MSC secretome reshapes the whole local cytokine environment, with effects that can carry across systems.
Targeted peptides, particularly BPC-157 and KPV, support gut epithelial integrity and reduce gut-derived inflammation. In chronic illness, where gut dysfunction is so often the upstream driver, this matters disproportionately.
The framing is mechanistic. We don’t promise outcomes, because chronic illness varies too much from patient to patient for that. We describe what these therapies do at the cellular level and let patients judge whether the biology lines up with what they’re experiencing.
Each protocol is designed individually by our medical team based on the specific diagnosis, history, and exposure profile. The four building blocks below are the ones most often deployed for chronic-illness cases.
An advanced class of mesenchymal stem cells bred to endure stress. They survive the inflammatory, oxidative, low-oxygen environments typical of chronic illness, where conventional MSCs often die before they can work. Delivered systemically by IV. Mitochondrial transfer is one of their most relevant actions in this cluster.
Learn MoreStem-cell-derived nanoparticles that carry the regenerative messaging without the cells themselves. They distribute systemically by IV and reach tissue beds that are difficult to dose with cellular therapy directly. Particularly useful for the broad multi-system inflammation that defines this cluster.
Learn MoreA targeted peptide stack: BPC-157 and KPV for gut barrier and inflammation; Thymosin Alpha-1 for immune balance; MOTS-c and SS-31 for mitochondrial bioenergetics specifically. The exact combination is built to the case, and not every patient gets every peptide.
Learn MoreNAD+ infusions directly support the mitochondrial cofactor pool that’s depleted in chronic illness. Vitamin C, glutathione, and amino-acid IVs underwrite the broader metabolic and antioxidant load. Often layered through the days surrounding cellular therapy.
Learn MoreMost chronic-illness protocols layer these together: systemic MSC and exosome IV, a peptide stack continued at home, and high-dose metabolic IVs to support bioenergetic and antioxidant capacity. Many patients return at 3–6 months for additional cellular dosing, since the underlying biology takes time to shift.
The chronic-illness cluster is not monolithic. Evidence quality varies, mechanism varies, and what’s reasonable to expect varies. Here’s where the science currently sits for the conditions we see most often.
Long COVID is the most-studied post-viral syndrome of the modern era and overlaps heavily with the rest of this cluster: persistent immune activation, mitochondrial dysfunction, and microvascular disturbance. The targets are the lingering inflammatory environment, the metabolic deficit, and the endothelial damage that drives many of the systemic symptoms.
MSC and exosome research in Long COVID is advancing rapidly through preclinical and early-phase clinical work. We coordinate cases with realistic framing about response variability, and we layer the cellular work with peptide and metabolic support designed for the post-viral context specifically.
Myalgic Encephalomyelitis / Chronic Fatigue Syndrome is the prototype of mitochondrial-dominated chronic illness. Post-exertional malaise, its hallmark feature, reflects an inability of mitochondria to recover after stress. It is a measurable cellular phenotype, not deconditioning and not psychological.
The regenerative approach targets mitochondrial bioenergetics directly through MSC mitochondrial transfer, MOTS-c and SS-31 peptides, and high-dose NAD+ infusions, layered with immune recalibration via MSC and exosome therapy. We’re explicit with patients that ME/CFS responds heterogeneously and that protocols need careful pacing.
Mycotoxin exposure and mast cell activation syndrome often co-occur and share an immunological signature: a hypersensitive, hyperreactive immune system stuck in constant low-grade activation. Standard care focuses on antihistamines and avoidance, which are necessary but often not enough.
Regenerative protocols in this cluster aim to recalibrate immune reactivity through MSC and exosome therapy, support gut barrier integrity through targeted peptides (BPC-157, KPV), and rebuild the metabolic capacity that’s been depleted by chronic immune activation. Clinical evidence is at an earlier stage than the post-viral data, but the mechanistic case is strong.
In every case the conversation starts with what’s known, what’s emerging, and what reasonable expectations look like. We don’t pitch outcomes. We describe mechanisms and let the evidence speak for itself.
Strong Craft Regen keeps an up-to-date repository of peer-reviewed research on regenerative medicine: the studies, mechanisms, and ongoing investigations that inform every protocol we coordinate.
Explore the Research